BeyondSpring (NASDAQ:BYSI) Shares Down 2.5% – What’s Next?

BeyondSpring Inc. (NASDAQ:BYSI)’s stock price fell 2.5% during mid-day trading on Monday . The stock traded as low as $1.51 and last traded at $1.58. 21,469 shares were traded during mid-day trading, a decline of 57% from the average session volume of 50,344 shares. The stock had previously closed at $1.62.

Analyst Ratings Changes

Separately, Weiss Ratings restated a “sell (d+)” rating on shares of BeyondSpring in a research note on Monday, December 29th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock has an average rating of “Sell”.

BeyondSpring Trading Down 2.5%

The business has a 50 day simple moving average of $1.83 and a two-hundred day simple moving average of $1.88. The stock has a market cap of $63.72 million, a price-to-earnings ratio of -10.53 and a beta of 0.55.

Institutional Trading of BeyondSpring

A hedge fund recently raised its stake in BeyondSpring stock. Geode Capital Management LLC grew its stake in shares of BeyondSpring Inc. (NASDAQ:BYSI) by 951.4% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 256,212 shares of the company’s stock after acquiring an additional 231,844 shares during the period. Geode Capital Management LLC owned about 0.64% of BeyondSpring worth $603,000 at the end of the most recent quarter. Institutional investors and hedge funds own 40.29% of the company’s stock.

About BeyondSpring

BeyondSpring Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing novel small-molecule therapies for oncology. Headquartered in Suzhou, China, with corporate operations in New York, the company leverages a versatile drug discovery platform to advance targeted treatments designed to improve outcomes for patients with cancer. BeyondSpring’s pipeline emphasizes agents that modulate the tumor microenvironment and enhance immune response, with an aim to address key unmet needs in supportive care and tumor control.

The company’s lead candidate, plinabulin, is a small-molecule vascular disrupting agent that also exhibits immunomodulatory activity.